Novel small molecules for animal health

The problem

The animal health industry has historically relied on human pharma as a low-cost source of innovation, leading to a lack of novel animal medicines.

The solution

Bringing the latest advances in drug discovery from human pharma to animal health by enabling ultra-fast, low-cost drug discovery specifically targeted at unmet needs in animal health.

Our engagement

Anterra incubated this company. Subsequent co-investors include Novalis Capital Partners and Finistere Ventures.